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Background: Isovaleric aciduria (IVA), propionic aciduria (PA) and methylmalonic aciduria (MMA) are inherited
organic acidurias (OAs) in which impaired organic acid metabolism induces hyperammonaemia arising partly from
secondary deficiency of N-acetylglutamate (NAG) synthase. Rapid reduction in plasma ammonia is required to
prevent neurological complications. This retrospective, multicentre, open-label, uncontrolled, phase IIIb study
evaluated the efficacy and safety of carglumic acid, a synthetic structural analogue of NAG, for treating
hyperammonaemia during OA decompensation.
Methods: Eligible patients had confirmed OA and hyperammonaemia (plasma NH3 > 60 μmol/L) in ≥1
decompensation episode treated with carglumic acid (dose discretionary, mean (SD) first dose 96.3 (73.8) mg/kg).
The primary outcome was change in plasma ammonia from baseline to endpoint (last available ammonia
measurement at ≤18 hours after the last carglumic acid administration, or on Day 15) for each episode. Secondary
outcomes included clinical response and safety.
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Results: The efficacy population (received ≥1 dose of study drug and had post-baseline measurements) comprised
41 patients (MMA: 21, PA: 16, IVA: 4) with 48 decompensation episodes (MMA: 25, PA: 19, IVA: 4). Mean baseline
plasma ammonia concentration was 468.3 (±365.3) μmol/L in neonates (29 episodes) and 171.3 (±75.7) μmol/L in
non-neonates (19 episodes). At endpoint the mean plasma NH3 concentration was 60.7 (±36.5) μmol/L in neonates
and 55.2 (±21.8) μmol/L in non-neonates. Median time to normalise ammonaemia was 38.4 hours in neonates vs
28.3 hours in non-neonates and was similar between OA subgroups (MMA: 37.5 hours, PA: 36.0 hours, IVA:
40.5 hours). Median time to ammonia normalisation was 1.5 and 1.6 days in patients receiving and not receiving
concomitant scavenger therapy, respectively. Although patients receiving carglumic acid with scavengers had a
greater reduction in plasma ammonia, the endpoint ammonia levels were similar with or without scavenger
therapy. Clinical symptoms improved with therapy. Twenty-five of 57 patients in the safety population (67 episodes)
experienced AEs, most of which were not drug-related. Overall, carglumic acid seems to have a good safety profile
for treating hyperammonaemia during OA decompensation.
Conclusion: Carglumic acid when used with or without ammonia scavengers, is an effective treatment for
restoration of normal plasma ammonia concentrations in hyperammonaemic episodes in OA patients.
Keywords: Carglumic acid, Hyperammonaemia, Organic acidurias (OAs), OA decompensation episodesFig. 1 Pathophysiology of hyperammonaemia in organic acidurias
and action of carglumic acid. CoA, coenzyme A; CPS-I, carbamoyl-
phosphate synthase I; NAG, N-acetylglutamate; NAGS, N-
acetylglutamate synthase; -, inhibition; +, activationBackground
Organic acidurias (OAs) are a group of rare inherited
diseases characterised by the excretion of non-amino or-
ganic acids in the urine. They result from the impaired
metabolism of organic acids, leading to abnormal and
toxic levels of organic acids in the blood, urine and tissues,
causing serious health problems [1, 2]. Three classical
OAs have been identified, namely isovaleric aciduria
(IVA), propionic aciduria (PA) and methylmalonic aciduria
(MMA). IVA is caused by a deficiency of isovaleryl-CoA
dehydrogenase, resulting in defective breakdown of leu-
cine. PA occurs due to a deficiency of propionyl-CoA
carboxylase and MMA is caused by a defect in the conver-
sion of methylmalonyl-CoA to succinyl-CoA, both of
which affect the metabolism of amino acids isoleucine,
valine, methionine and threonine [1].
OAs usually develop in the neonatal period, charac-
terised by toxic encephalopathy within the first few days
of life, with symptoms including vomiting, poor feeding,
seizures and abnormal tone, and lethargy progressing to
coma [3, 4]. This metabolic decompensation is a medical
emergency that can be fatal or result in brain damage if
patients do not receive immediate medical interventions
[2]. Mechanisms for acute encephalopathy include direct
neurotoxicity of metabolites and hyperammonaemia [1, 5].
Normally the level of ammonia is controlled by conversion
to urea in the liver and subsequent excretion in urine. In
the classical OAs, propionyl CoA, methylmalonyl CoA and
isovaleryl CoA accumulate and inhibit N-acetylglutamate
(NAG) synthase (NAGS). NAGS catalyses the formation of
NAG, an activator required by carbamoyl-phosphate syn-
thetase I (CPS-I). CPS-I is a key enzyme of ureagenesis that
catalyses the first and rate-limiting step of the urea cycle
[6–9]. Propionyl CoA and methylmalonyl CoA also inhibit
the pathway by depleting hepatic acetyl CoA, which isrequired for NAG synthesis. Figure 1 provides an overview
of the mechanism of hyperammonaemia in OAs.
Reducing ammonia levels as quickly as possible is one
of the medical priorities in acute decompensation epi-
sodes of OAs as a longer duration and higher levels of
hyperammonaemia are associated with worse neuro-
logical outcomes [10]. First-line management includes
the promotion of anabolism through the administration
of high calorie energy sources, such as intravenous
glucose and a protein-restricted diet [7]. Ammonia scav-
engers such as sodium benzoate and sodium phenylbu-
tyrate (excreted as hippurate and phenylacetylglutamine
after conjugation with glycine or glutamine, respectively
[11, 12]) have a higher renal clearance than ammonia it-
self, and are therefore used for accelerating ammonia
elimination in the urine [7]. Haemodialysis or peritoneal
dialysis may be started if these interventions do not
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within a few hours.
Carglumic acid is a synthetic structural analogue of
NAG, and as such is a specific intervention for hyperam-
monaemia in these patients. This was approved as
Carbaglu® by the European Medicines Agency (EMA) for
the treatment of hyperammonaemia due to primary
NAGS deficiency, and hyperammonaemia due to IVA,
MMA and PA [13]. Carglumic acid accelerates ammonia
detoxification by mimicking the effects of NAG on CPS-
I, thereby driving the urea cycle forward independent of
other mechanisms for detoxifying the organic acids
(Fig. 1). In the first published clinical study, Ah Mew et
al. showed that single dose/short-term treatment with
carglumic acid was associated with reduced ammonia
and glutamine levels and an increase in ureagenesis [8].
Carglumic acid has been used in humans since 1981 in
the acute and long-term treatment of NAGS deficiency.
Although a number of publications describe the re-
sponse to, and safety of carglumic acid in the treatment
of hyperammonaemia due to OA decompensation epi-
sodes or NAGS primary deficiency [7, 8, 14, 15], carglu-
mic acid’s orphan drug status highlights the need for
further research into its effectiveness in treating OA-
induced hyperammonaemia in various age groups and in
patients with different aetiologies of hyperammonaemia.
This retrospective, multicentre, open-label, uncon-
trolled, phase IIIb study was designed to evaluate the effi-
cacy and safety of carglumic acid in OA patients with
hyperammonaemia during metabolic decompensation epi-
sodes. The primary objective of this study was to study
the change in plasma ammonia levels as the main bio-
logical response to carglumic acid treatment during epi-
sodes of hyperammonaemia in OA. Secondary objectives
include describing the demographic profile of the patient
population, evaluating the clinical and biological responses
to treatment and assessing the safety of carglumic acid.
Ethics, consent and permissions
This study was conducted in accordance with Good
Clinical Practice, the Principles of the Declaration of
Helsinki and the requirements of local ethics committees
(Spain: Comité Etico de Investigacion Clinica de Aragon,
Avda. San Juan Bosco, Zaragoza; Comité Etico de
Investigacion Clinica Hospital Clinico Universitarion de
Valencia, Avda. Vicente Blasco Ibanez, Valencia. France:
Comité de Protection des Personnes Ile De France II,
Centre Universitaire des Saints-Pères, rue des Saints-
Pères, Paris. Italy : Comitato Etico dell Azienda, Ospeda-
liera Policlinico Consorziale di Bari; Comitato Etico
Locale per la sperimentazione dei farmaci, dell’azienda
ospedaliero-Universitaria Anna Meyer de Firenze. UK:
Leicestershire, Northamptonshire and Ruland Ethics
Committee 2, Nottingham. Germany: Ethik-kommissiondes Fachbereichs Medizin der Johann Wolfgang
Goethe-Universitat, Frankfurt. Netherlands: Stichting
CGR Hanzeweg, Goud.)
Informed consent was obtained for each patient prior
to commencement of the planned data collection, review
and analysis. Cases where circumstances made it neces-
sary to waive informed consent (eg if the patient was
dead or lost to follow-up) were dealt with on a case by
case basis and in accordance with local regulations.
Methods
Data were collected from 21 centres in Italy, France,
Germany, the Netherlands, Spain, Turkey and the
United Kingdom from patients treated between January
1995 and October 2009.
Patient eligibility
Eligible patients had a confirmed diagnosis of OA with
hyperammonaemia (defined as plasma NH3 concentra-
tion above 60 μmol/L before carglumic acid treatment)
during at least one full OA decompensation episode that
was treated with carglumic acid. Patients with severe
hepatic insufficiency at the time of carglumic acid treat-
ment, inherited hepatic malformation, or intercurrent
disease (other than OA) that might have generated
hyperammonaemia were excluded from the study.
Study treatment
As a retrospective, observational study, dosing regimens
were not predefined. The recommended initial dose of
carglumic acid in Europe is 100–250 mg/kg/day, admin-
istered orally twice or thrice daily. Carglumic acid doses
in this study were at the discretion of the treating phys-
ician, as was the duration of treatment. However, the
evaluation window was defined as up to a maximum of
15 days from the first administration of carglumic acid.
Some patients were treated with ammonia scavenger
medications, including sodium benzoate and sodium
phenylbutyrate, prior to and/or concomitantly with car-
glumic acid.
Study evaluations and endpoints
All available retrospective efficacy and safety data were
collected for each OA decompensation with hyperam-
monaemia episode. A single episode of hyperammonae-
mia was defined as an acute episode lasting up to
15 days (defined based on expert opinion and previous
experience and assessed by the investigators based on
both ammonia levels and clinical symptoms). If treat-
ment with carglumic acid was discontinued before Day
15 and there was a >20 % increase of plasma ammonia
compared with the last measurement that occurred be-
yond 24 hours after discontinuation, this was considered
a new episode. If carglumic acid treatment was
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monia compared with the last measurement was re-
corded as a new episode. Efficacy measurements were
assessed at baseline, defined as the evaluation just prior
to initiation of carglumic acid treatment for each epi-
sode, and at the study endpoint, defined as end of treat-
ment (no more than 18 hours after the last intake of
carglumic acid) or the last available value under treat-
ment up to a maximum of 15 days.
The primary evaluation was plasma NH3 concentra-
tion at the study endpoint. Normalisation of plasma
NH3 concentration was defined as plasma NH3 concen-
tration ≤60 μmol/L. Secondary evaluations at study end-
point included other biological markers (plasma amino
acids, plasma and urinary organic acids and blood bio-
chemistry), clinical markers of neurological, psychiatric,
psychomotor, respiratory and hepatic status, and safety
assessments. Time to reach plasma NH3 ≤ 60 μmol/L
was also assessed.
Statistical analysis
Analysis was carried out on episodes of hyperammonae-
mia in the efficacy population, as a single patient could
have more than one episode. The efficacy population in-
cluded all enrolled patients who received at least one
dose of carglumic acid and had a baseline and endpoint
plasma NH3 measurement for the same episode. Patients
or episodes were excluded from the efficacy analyses if
there was one or more major protocol deviation such as
missing NH3 data at baseline or endpoint, unconfirmed
diagnosis or deviations relating to the inclusion/exclu-
sion criteria.
Descriptive analyses were performed, with continuous
variables summarised by descriptive statistics (number
of patients [n], mean, standard deviation, minimum, me-
dian and maximum) and categorical data presented by
absolute and relative frequencies (n and %). Unless
otherwise indicated, summary statistics were reported
for observed data only.
The primary evaluation was analysed using a repeated
measures analysis of change from baseline in plasma
NH3 concentration at study endpoint for all episodes.
The least squares mean change and 95 % confidence in-
tervals (CI) are reported. Missing data were not imputed.
Secondary evaluations were analysed in a similar man-
ner. Subgroup analyses of the primary and secondary
evaluations were performed, including OA type, neonate
(≤28 days of age at start date of carglumic acid treat-
ment) vs non-neonate and use of ammonia scavenger
medications and/or haemodialysis/haemofiltration.
The safety population was defined as all patients
exposed to at least one dose of study drug; safety ana-
lyses comprised incidence of treatment-emergent ad-
verse events (TEAEs), clinical laboratory parameters andconcomitant medications. Drug-related AEs were de-
fined as those considered by the investigator as being ei-
ther related to use of the study drug or of unknown
causality.
Results
Patient disposition
Fifty-seven patients, of whom 64.9 % were neonates,
were included in the study and constituted the safety
population; most of these were treated for a single epi-
sode of hyperammonaemia (48 patients; 84.2 %; Fig. 2).
Seventeen patients had major protocol deviations, result-
ing in exclusion from the efficacy analyses; however one
patient had a protocol deviation for one of the two re-
corded episodes, and thus remained in the efficacy
population. Of the 41 patients in the efficacy population,
35 had a single recorded episode of hyperammonaemia
treated with carglumic acid (Fig. 2). The remaining epi-
sodes within the efficacy population were experienced by
five patients who had two episodes and one patient who
had three episodes.
Additional management with a low protein diet was
recorded in 73 % of the 26 episodes with available data
at baseline and 59 % of the 39 episodes with available
data at study endpoint. Furthermore, treatment with at
least one of L-carnitine, L-glycine or L-arginine, before
and/or during treatment with carglumic acid, was ad-
ministered in 38 and 58 episodes within the efficacy and
safety populations, respectively.
Episode characteristics in the efficacy population
Of the 48 hyperammonaemia episodes included in the
efficacy analysis, 29 occurred in neonates and 19 in non-
neonates. MMA and PA were the most common OA
diagnoses (Fig. 2). The mean duration of episodes ranged
from 5.0 to 9.8 days for the different OAs and was
shorter in neonates compared with non-neonates
(Table 1). The median age at presentation with a
study episode was 0.2 and 12.7 months for neonates
and non-neonates, respectively.
Twenty-one of the 48 hyperammonaemia episodes
(44 %) in the efficacy population were treated with add-
itional ammonia lowering therapy, such as ammonia
scavengers and haemofiltration, before or during carglu-
mic acid treatment. Similar patterns of use were seen in
the MMA and PA efficacy populations, although none of
the IVA episodes were treated with additional ammonia
lowering therapy. Use of additional ammonia lowering
therapy was higher in neonates compared to non-
neonates (Table 1).
Carglumic acid treatment was discontinued in the ma-
jority of cases due to the patient reaching the end of an
episode (86.7 %). Discontinuation due to death and other
reasons such as a dramatic decrease of ammonia plasma
Fig. 2 Participant flow. *Includes one patient treated twice as a neonate. †Some cases excluded for multiple reasons. IVA, isovaleric aciduria;
MMA, methylmalonic aciduria; NH3, ammonia; PA, propionic aciduria
Table 1 Episode characteristics by patient diagnosis in the efficacy population
Isovaleric aciduria Methylmalonic aciduria Propionic aciduria Neonates Non-neonates Total
N, patients 4 21 16 28 13 41
Gender
Male 2 9 11 14 8 22
Female 2 12 5 14 5 19
N, episodes 4 25 19 29a 19 48
Median age at episode, days 7 (neonate) 5 (neonate) 6.5 (neonate) 6 387 6.0 (neonate)
387.0
(non-neonate)
Median age at episode,
months
44.84
(non-neonate)
2.53
(non-neonate)
12.73
(non-neonate)
0.20 12.73 0.2 (neonate)
12.73
(non-neonate)
Duration of episode,
Mean, days (SD) 5.0 (1.8) 7.8 (6.0) 9.8 (10.5) 6.6 (4.8) 11.0 (10.8) 8.4 (7.9)
Median, days 5.0 7.0 6.0 6.0 7.0 6.0
Range, days 3–7 2–26 2–43 2–20 3–43 2–43
Concomitant treatmentb (%) 0 (0.0) 12 (48.0) 9 (47.4) 18 (62.1) 3 (15.8) 21 (43.8)
Scavengers 0 9 6 13 2 15
Haemodialysis/haemofiltration 0 3 3 5 1 6
Baseline NH3, μmol/L
Mean (SD) 666.8 (692.2) 296.9 (206.2) 355.0 (326.8) 468.3 (365.3) 171.3 (75.7) 350.7 (321.3)
Median 435.0 247.8 213.0 328.0 164.0 215.0
Range 164.0–1633.0 76.1–868.0 76.0–1200.0 96.0–1633.0 76.0–385.0 76.0–1633.0
aOne patient was treated for two episodes of hyperammonaemia within 28 days of birth
bConcomitant treatment includes ammonia scavengers and haemodialysis/haemofiltration
SD, standard deviation
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Fig. 4 Ammonia levels in response to carglumic acid therapy by age
category.* Ammonia levels in the neonate group were higher than
those in the non-neonate group at baseline; however, both groups
achieved a similar endpoint ammonia level within the same timeframe
(18 hours). *Analysis by episode in the efficacy population; shaded grey
area is target plasma ammonia concentration
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malisation of ammonaemia were seen in 4.4 % and 8.9 %
of episodes, respectively. No differences in the reasons
for discontinuation of carglumic acid were noted between
neonates and non-neonates.
Ammonia profile in response to carglumic acid treatment
Following initiation of carglumic acid treatment, the high
average baseline levels of plasma NH3 (Table 1) decreased
rapidly to levels close to the normalisation level of
60 μmol/L by Day 3 of treatment in all three OA subgroups
(Fig. 3). Generally plasma NH3 levels were maintained over
the two week follow-up period. Similar mean endpoint
plasma NH3 concentrations were seen when summarised
by diagnostic subgroup, ie MMA, 67.7 ± 36.4 μmol/L;
IVA, 52.5 ± 28.4 μmol/L; PA, 47.8 ± 20.4 μmol/L.
The endpoint mean plasma NH3 concentration was
60.7 ± 36.5 μmol/L for neonates and 55.2 ± 21.8 μmol/L
for non-neonates (Fig. 4). The primary evaluation of mean
change in plasma NH3 concentration from baseline to
endpoint for the total efficacy population revealed a mean
(95 % CI) reduction of -292.2 (-385.4 to -199.0) μmol/L.
The mean changes in plasma NH3 concentration from
baseline to endpoint for the different subgroups are given
in Table 2, while the mean changes in plasma NH3 from
baseline to achievement of a normalised ammonia level
(≤60 μmol/L) are provided in Table 3.
The median time to achieve normalisation of plasma
NH3 concentration after initiation of carglumic acid
treatment for the episodes treated with ammonia lowering
therapy was 36.5 hours and without 37.4 hours. The me-
dian time to achieve NH3 ≤ 60 μmol/L among the three
analysed OA subgroups was 40.5 hours for IVA; 37.5 hours
for MMA; 36 hours for PA. The median time to achieve
normalisation of plasma NH3 concentration was 38.4 hours
in the neonate group and 28.3 hours in the non-neonate
group. Concomitant use of haemodialysis/haemofiltrationFig. 3 Ammonia profile in response to carglumic acid treatment.
Endpoint NH3 in response to treatment with Carbaglu® for each of
the diagnostic groups was 52.5 μmol/L (IVA), 67.7 μmol/L (MMA)
and 47.8 μmol/L (PA). The time to achieve endpoint was equivalent
for the three groups. IVA, isovaleric aciduria; MMA, methylmalonic
aciduria; PA, propionic aciduria. Analysis by episode for the total
efficacy population and for diagnosis subpopulationswas associated with a higher rate of change in plasma NH3
concentration from baseline to study endpoint. The
median baseline plasma NH3 level was 506.5 μmol/L in pa-
tients who received haemodialysis/haemofiltration com-
pared to 206 μmol/L in patients who did not receive these
treatments; at endpoint the median plasma NH3 levels
were reduced to 31 μmol/L and 55.5 μmol/L, respectively.
However the number of episodes treated with haemodialy-
sis/haemofiltration was low (n = 6). It was noted that the
episodes concomitantly treated with scavengers were the
more severe cases associated with higher levels of plasma
NH3 at baseline.
Clinical symptoms
At baseline all 48 episodes were associated with clinical
symptoms, including poor sucking, vomiting, muscle
hypotonia, hyperventilation, lethargy, coma and recur-
rent ketoacidosis. At the end of the episodes with avail-
able baseline and endpoint data, there were no clinical
symptoms in 8 of 30 (26.7 %) episodes. At baseline only
12 % of episodes (3/25 episodes with available baseline
and study endpoint data) occurred in patients with nor-
mal neurological status compared with 52 % (13/25) of
episodes at study endpoint. The most commonly ob-
served neurological symptom was somnolence, the
prevalence of which decreased from 68 % at baseline to
28 % at study endpoint.
A lower incidence of clinical symptoms was observed
at study endpoint compared with baseline where data
were available at both time points. Normal psychiatric
status was recorded in 87.5 % (21/24) of episodes at
study endpoint compared with 70.8 % (17/24) at base-
line. Similarly, normal hepatic status and normal respira-
tory status were seen in 84.4 % (27/32) and 83.9 %
(26/31) of episodes, respectively at study endpoint
compared with 75.0 % (24/32) and 61.3 % (19/31)
episodes, respectively at baseline. The incidence of
Table 2 Change in plasma ammonia concentration from baseline to study endpoint in efficacy population
Episodes n Mean change in NH3
at endpoint (μmol/L)
Mean time to the
endpoint, days
Total 48 -292.2 4.6
Isovaleric aciduria 4 -614.3 2.8
Methylmalonic aciduria 25 -229.2 5.2
Propionic aciduria 19 -307.3 4.2
Neonates 29 -407.6 4.0
Non-neonates 19 -116.1 5.6
With concomitant ammonia scavengers 15 -366.0 3.9
Without concomitant ammonia scavengers/haemofiltration 27 -200.2 5.0
With haemofiltration (with or without ammonia scavengers) 6 -521.8 4.8
NH3, ammonia
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and at study endpoint [16/25]).
Safety evaluations
Overall, in this retrospective observational study in pa-
tients with OA, 25 of 57 patients in the safety population
experienced at least one AE (Table 4). A total of 74 AEs
were reported, including 23 severe AEs and 22 serious
AEs (SAEs). The reported AEs were mainly from four
system organ classes: general disorders and administra-
tion sites conditions (15.8 %), blood and lymphatic
system disorders (14.0 %), infections and infestations
(12,3 %), and metabolism and nutrition disorders
(12.3 %). There were 11 SAEs in seven patients that re-
sulted in death. These patients died from usual compli-
cations observed during episodes of decompensation in
OA, such as cardiogenic shock, multi-organ failure,
metabolic disorders and respiratory arrest.
All these deaths were thought by the investigators to
be unrelated to carglumic acid, except for in one patient
who had neurological symptoms prior to study drug ad-
ministration (poor sucking, muscle hypotonia, lethargyTable 3 Change in plasma ammonia concentration from baseline to
Epis
Total 42
Isovaleric aciduria 3
Methylmalonic aciduria 20
Propionic aciduria 19
Neonates 24
Non-neonates 18
With concomitant ammonia scavengers 14
Without concomitant ammonia scavengers 22
With haemofiltration (with or without ammonia scavengers) 6
aNormalised plasma ammonia defined as NH3 ≤ 60 μmol/L
bEfficacy population
NH3, ammoniaand somnolence). He died due to neurological damages
and respiratory arrest six days after discontinuation of
carglumic acid (given for nine days), and therefore the
causality of neurological damage probably leading to
death seems unlikely to be related to carglumic acid
treatment.
Treatment initiation, dosage and treatment duration
The mean time between the start of an episode and initi-
ation of carglumic acid was 3 days for the total efficacy
population (Table 5). For the individual diagnoses, the
mean time to initiation of treatment was 0.8 (IVA), 2.5
(MMA) and 4.2 (PA) days. In neonates, the mean time
from the start of an episode to the beginning of treat-
ment was 1.5 days, while in non-neonates it was 5.3 days.
For the efficacy population, the mean (SD) length of car-
glumic acid treatment was 5.5 (4.6) days. Mean (SD)
length of treatment was 4.9 (3.5) days for neonates and
6.5 (5.9) days for non-neonates.
The mean first dose of carglumic acid for episodes in
the efficacy population was 96.3 mg/kg. In neonates, the
mean first dose of carglumic acid was 106.7 mg/kg,achievement of normalised plasma ammoniaab
odes n Mean change at
NH3 ≤ 60 μmol/L
Mean time to achieve
NH3 ≤ 60 μmol/L, days
-272.8 2.4
-299.0 2.3
-233.1 1.9
-310.5 3.0
-392.6 2.0
-113.2 3.1
-344.7 2.3
-157.2 2.8
-529.3 1.5
Table 4 Summary of treatment-emergent adverse events in the
safety population
Events (%) Patients (%)
n = 57
Any AEs 74 25 (43.9)
All severe AEs 23 (31.1) 13 (22.8)
All serious AEs 22 (29.7) 13 (22.8)
All drug-related AEsa 24 (32.4) 9 (15.8)
All serious drug-related AEsb 6 (8.1) 5 (8.8)
All AEs leading to death 11 (14.9) 7 (12.3)
aAEs with an investigator’s causality assessment of either ‘related’ or
‘unknown’. Of these, none were assessed as ‘related’
bAll serious drug-related AEs with an investigator assessment of ‘related’ or
‘unknown’. Of these, only one was assessed by the investigator as ‘related’ and
this was neurological damage that resulted in death
AEs, adverse events
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80.4 mg/kg. The first dose of carglumic acid in pa-
tients concomitantly treated with ammonia scavengers
was 125.4 mg/kg (mean) and 106.4 mg/kg (median).
Patients not treated with ammonia scavengers received a
mean dose of 73.6 mg/kg (median: 50.0 mg/kg). However,
a wide range of first dose sizes was administered in all
groups (Table 5). The most common initial 24-hour dose
category was 100–250 mg/kg, with the mean 24-hour car-
glumic acid across all patients being 184.5 mg/kg (Table 5).
The initial daily dose of carglumic acid administered to
the total efficacy population was consistent with the EMA
label (100–250 mg/kg). Dose reductions during the course
of treatment resulted in a shift from a predominance of
doses in the 100–250 mg/kg range to a relatively even dis-
tribution of episodes treated with these doses and lower
doses of 50–100 mg/kg and <50 mg/kg.Table 5 Treatment initiation, dosage and treatment duration in the
Isovaleric aciduria
(n = 4)
Methylmalonic aciduria
(n = 25)
Pro
(n =
Time to treatment initiation
Mean, days (SD) 0.8 (1.0) 2.5 (5.5) 4.2
Median (range) 0.5 (0–2) 0.0 (0–24) 2.0
First dose
Mean, mg/kg (SD) 99.0 (63.3) 78.2 (64.9) 119
Median, mg/kg (range) 81.6 (50.0–182.7) 51.0 (13.7–236.2) 106
Initial 24-h dose
Mean, mg/kg (SD) 216.0 (217.9) 160.6 (108.3) 209
Median, mg/kg (range) 131.6 (62.5–538.5) 129.0 (41.1–470.8) 190
Treatment duration
Mean, days (SD) 3.5 (1.7) 6.1 (4.6) 5.2
Median, days (range) 3.5 (2–5) 5.0 (1–15) 3.0
SD, standard deviationDiscussion
This study demonstrated that carglumic acid, with or
without additional therapies such as ammonia scaven-
gers, induced a rapid and effective reduction of plasma
ammonia during decompensation episodes in OAs. It
represents the largest body of evidence to date on the
efficacy and safety of carglumic acid in the management of
hyperammonaemia in patients with OAs. Mean reductions
to similar ammonia levels at study endpoint were seen in
patients with IVA, MMA and PA. Furthermore, carglumic
acid treatment of hyperammonaemia episodes reduced
plasma NH3 concentrations to similar levels in neonates
and non-neonates, despite neonatal episodes having higher
ammonia concentrations at treatment initiation. These data
support the use of carglumic acid in the treatment of
hyperammonaemia in neonates and non-neonates with any
of the three classical OA types. Reductions in plasma NH3
concentration following carglumic acid treatment were
accompanied by improvements in clinical symptoms and
neurological status.
Mean plasma NH3 concentration at endpoint was
similar in patients treated with scavengers compared to
those not treated with scavenger medication (55.6 vs
60.8 μmol/L). However, mean baseline NH3 concentra-
tion was higher in the group of patients who received
scavengers (466.1 vs 261.0 μmol/L). When the higher
baseline NH3 level is considered, there was a higher rate
of change in plasma NH3 levels in patients treated with
scavengers (-410.5 vs -200.2 μmol/L). Reduction in
plasma NH3 concentration was more rapid in episodes
of hyperammonaemia treated with carglumic acid and
scavengers compared with those not treated with scav-
engers. These analyses were repeated excluding one out-
lier, who experienced a very rapid and large decrease inefficacy population
pionic aciduria
19)
Neonates
(n = 29)
Non-neonates
(n = 19)
Total
(n = 48)
(9.5) 1.5 (2.8) 5.3 (10.6) 3.0 (7.2)
(0–41) 1.0 (0–14) 1.0 (0–41) 1.0 (0–41)
.5 (83.2) 106.7 (75.3) 80.4 (70.5) 96.3 (73.8)
.0 (13.3–303.0) 100.0 (13.7–303.0) 50.0 (13.3–256.4) 75.5 (13.3–303.0)
.3 (186.9) 214.1 (179.1) 139.2 (81.7) 184.5 (151.8)
.2 (53.1–909.1) 170.2 (41.1–909.1) 100 (45.3–333.3) 156.4 (41.0–909.1)
(5.0) 4.9 (3.5) 6.5 (5.9) 5.5 (4.6)
(1–15) 4.0 (1–15) 3.0 (1–15) 4.0 (1–15)
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the hyperammonaemia episodes treated with scavengers
were more severe at presentation and scavenger use was
more frequent in neonates, thus the observed differences
between these groups are unsurprising. As expected, the
use of haemodialysis prior to or concomitantly with car-
glumic acid was also associated with a more rapid re-
sponse. Although use of scavengers may be beneficial by
increasing reduction of plasma NH3 levels, there are a
number of potential disadvantages to be considered. So-
dium phenylacetate may induce glutamine depletion as
it conjugates with glutamine to yield phenylacetylgluta-
mine, which is subsequently excreted in the urine [16].
Additionally, sodium phenylacetate and sodium benzoate
may potentiate ammonia toxicity by blocking the urea
cycle through sequestration of CoA [17, 18] and caution
when used in organic acidemias was suggested by recent
guidelines [19]. Moreover, treatment with these scaven-
ging drugs at high doses may increase serum sodium
and decrease serum potassium levels [18]. Consequently,
measuring plasma levels of sodium benzoate is recom-
mended in the neonatal period, particularly in jaundiced
infants; however, this analysis is not available in most
centres [18].
The response to carglumic acid with or without am-
monia scavengers in neonates was faster than in non-
neonates; however, it is difficult to separate the effects of
scavenger treatment from the effects due to age. The
rapidity of response in non-neonates was similar with or
without scavengers; however, more data are needed as
only two non-neonates were treated with scavengers in
this study. The time to response following carglumic
acid administration was similar in patients with MMA
and PA. The small number of patients with IVA and the
high plasma NH3 concentration at treatment initiation
in these patients make it difficult to draw conclusions on
the time to response compared with the other OAs.
The relatively small number of IVA cases in this study
(n = 4) is consistent with the frequency observed in clin-
ical practice. Clinical experience suggests that patients
with IVA have less severe hyperammonaemia [5, 20] and
are easier to manage compared to patients with other
OAs.The higher baseline ammonaemia in the IVA epi-
sodes in this study suggests that only the most severe
cases were treated with carglumic acid. In addition, this
small sample population had an artificially high mean
and median plasma NH3 concentration due to an outlier
(1633 μmol/L). The larger number of neonates (n = 28)
compared with non-neonates (n = 13) included in the
study reflects the more severe hyperammonaemia seen
in neonates at presentation [3]. Unsurprisingly, higher
doses of carglumic acid were administered to neonates,
as in general the more severe hyperammonaemia epi-
sodes were treated with high doses. Similarly episodes inneonates vs non-neonates were more frequently con-
comitantly treated with scavengers, as they were more
severe cases with higher baseline plasma NH3 levels.
Dietary management is often used as first-line treat-
ment in the management of decompensation episodes
[19, 21]; however, the impact is limited as an extremely
restricted diet cannot be maintained for more than
48 hours [19]. Carglumic acid treatment might allow a
faster reintroduction of protein into the diet and thus
limit muscular catabolism contributing to hyperammo-
naemia as seen in the context of NAGS deficiency [22].
The clinical presentation of patients with metabolic
decompensation at baseline was consistent with other
reports in the literature [19], with marked neurological
and gastrointestinal symptoms as well as anaemia, keto-
sis and metabolic acidosis. Eight patients were comatose
prior to treatment with carglumic acid. A total of 23 pa-
tients presented with lethargy. At study endpoint,
gastrointestinal and neurological symptoms, ketoacidosis
and hyperventilation were significantly reduced com-
pared to baseline.
Analysis of data from the safety population showed
carglumic acid to have a good safety profile. The number
of deaths (n = 7) is not unexpected, as OA has a high
mortality rate. Mortality rates of approximately 50 %
have been reported, however these are related to long-
term outcomes and cannot be directly compared with
this study [1, 23]. The time between start of an episode
and initiation of carglumic acid treatment was similar
for the three diagnostic categories. The mean time be-
tween start of an episode and initiation of carglumic acid
treatment was longer in non-neonates compared to neo-
nates, however the median time was similar. The mean
duration of treatment for hyperammonaemia was similar
in both neonates and non-neonates. Treatment with car-
glumic acid was largely initiated at the EMA label rec-
ommended dose (100–250 mg/kg). While dose was
decreased over time, this decrease was not pronounced.
A high first dose of carglumic acid, albeit within the rec-
ommended dose range of 100–250 mg/kg, is consistent
with the fact that treatment often commences with a
loading dose for rapid normalisation of plasma ammonia
levels [24] and subsequently a daily dose based on
weight and hyperammonaemia severity is administered
[13]. There was significant variation between regimens
(eg whether the loading dose was high or low) making
an analysis by dose quite difficult.
This retrospective study has a number of limitations,
including lack of control patients treated only with scav-
engers, patient data variability, the inability to adjust for
confounders (including concomitant drugs and diet) and
the small number of patients in analysis subgroups.
We are currently looking into a new follow-up retro-
spective study designed to compare carglumic acid to
Valayannopoulos et al. Orphanet Journal of Rare Diseases  (2016) 11:32 Page 10 of 11ammonia scavengers and/or hemofiltration, provided
that an equivalent number of hyperammonemic episodes
would be retrieved in the same period of time with in-
clusion criteria being treatment by ammonia scavengers
or hemofiltration. Such a study would still present limi-
tations, as it would be unlikely to match the same num-
bers of episodes with the same treatment modalities (i.e.
1 or 2 scavengers, with or without hemofiltration).
Also, a prospective study with ammonia scavengers
only would raise ethical questions since carglumic acid
is now an approved drug for treating hyperammonemia
in organic acidemias.
Nevertheless, the current study with its observational de-
sign provides valuable information regarding real-life clin-
ical practice and the response of patients who have been
treated according to local protocols and subject to the clin-
ical judgement of physicians on a case-by-case basis.
Data from this study are consistent with other pub-
lished data supporting the use of carglumic acid in PA
[8]. Furthermore, Daniotti et al. reported that carglumic
acid improves acute therapy and reduces the need for
the duration of peritoneal dialysis and haemodialysis [7],
and recommended that carglumic acid be initiated as
soon as possible, even before confirmation of the exact
diagnosis. Indeed, although recent guidelines focus on
the use of carglumic acid in NAGS deficiency, the use of
carglumic acid in hyperammonaemic patients with sus-
pected NAGS deficiency is also recommended [19].Conclusion
The results of this study indicate that carglumic acid at
the recommended initial dose of 100–250 mg/kg/day,
with or without ammonia scavengers, is an effective and
safe treatment to restore normal plasma ammonia con-
centrations (<60 μmol/L) in episodes of hyperammonae-
mia occurring during metabolic decompensation in
patients with IVA, MMA, and PA.
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